News

Xolair Improves Quality of Life in Chronic Idiopathic Urticaria Patients with Angioedema, Study Says

In a Phase 3 clinical trial in Germany, the therapy Xolair (omalizumab) was shown to improve the quality of life and psychological well-being of chronic idiopathic urticaria (CIU) patients with angioedema who were resistant to treatment with antihistamines. Results were highlighted in the study, “Omalizumab rapidly improves angioedema-related…

NIH Agency Pioneers Collaborative Research into Rare Diseases

A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…

EMA Quickens Review of Lanadelumab for Hereditary Angioedema

The European Medicines Agency (EMA) will begin an accelerated review of Shire’s lanadelumab, a treatment candidate to prevent hereditary angioedema (HAE) swelling attacks, the company announced. This follows the EMA’s acceptance of Shire’s marketing authorization application (MAA) for the potential therapy, which reduces the number of days…